General
Preferred name
TIAPRIDE
Synonyms
TIAPRIDE HYDROCHLORIDE ()
Tiapride (hydrochloride) ()
Gramalil ()
Sereprile ()
Italprid ()
Tiapride hcl ()
Luxoben ()
Tiapridex ()
Tiapridal ()
Tiaprida ()
NSC-758225 ()
P&D ID
PD013238
CAS
51012-32-9
51012-33-0
Tags
available
drug candidate
drug
Drug indication
Anxiety
Huntington disease
Alcohol dependence
Neuropathic pain
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Tiapride hydrochloride is a selective and orally active D2 and D3 dopamine receptors antagonist with IC50 values of 110-320 nM and 180 nM, respectively. Tiapride hydrochloride shows anti-dyskinetic activity and anxiolytic activity. Tiapride hydrochloride is a neuroleptic agent[1][2].
PHARMACODYNAMICS
Tiapride has a high degree of regional selectivity for limbic areas. One study found that tiapride shows over three times as much affinity for limbic areas than striatal areas as opposed to the near equal selectivity for limbic and striatal regions shown by haloperidol.; Another study in rats found tiapride's affinity for the septum, a limbic region, to be over thirty times as high as for the striatum.; Efficacy at the D2 receptor is moderate, with 80 percent of receptors occupied even in the presence of excess tiapride concentrations.
MOA
Tiapride is a selective dopamine D2 and D3 receptor antagonist, offering an advantage over other neuroleptic drugs, such as haloperidol and risperidone, which bind a range of targets including four of the five known dopamine receptor subtypes (D1-4), serotonin (5-HT2A, 2C), α1- and α2-adrenergic, and histamine H1 receptors. Compared to these drugs, tiapride has a relatively moderate affinity for its target receptors, displacing 50 percent of 3H-raclopride binding at a concentration of 320 nM at D2 receptors and a concentration of 180 nM at D3 receptors.
ABSORPTION
The bioavailability of tiapride is approximately 75 percent. It has a Tmax is 0.4-1.5 hours and Tss is 24-48 hours with 3 time daily dosing. Benzamide and its derivatives are highly water-soluble but known to cross the blood-brain barrier, necessitating carrier-mediated transport.
DESCRIPTION
D2 and D3 dopamine receptor antagonist; antipsychotic
(LOPAC library)
DESCRIPTION
Tiapride is a selective blocker of D2/3 dopamine receptors in the brain. It is used in the therapy of various psychiatric and neurological disorders containing dyskinesia, negative symptoms of psychosis, alcohol withdrawal syndrome, and aggression and agitation in the elderly.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain. Tiapride is indicated for the treatment of a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
20
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Ki Database
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
52
Molecular Weight
328.15
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
1
Aromatic Ring Count
1
cLogP
1.17
TPSA
75.71
Fraction CSP3
0.53
Chiral centers
0.0
Largest ring
6.0
QED
0.78
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
D2/D3
Target
D2
D3
dopamine
DRD2, DRD3
Dopamine Receptor
Indication
dyskinesia, abstinence from alcohol, psychosis
MOA
Dopamine Receptor antagonist
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Source data

